Trials / Recruiting
RecruitingNCT06300528
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
PERFORM: A Phase II Study of Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (estimated)
- Sponsor
- University of Utah · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical trial is to learn if the study drug pemigatinib is effective in treating patients with relapsed or refractory B-cell non-Hodgkin lymphomas.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pemigatinib | Pemigatinib will be self-administered as a once-a-day oral treatment on a 28-day cycle. |
Timeline
- Start date
- 2025-10-03
- Primary completion
- 2027-01-01
- Completion
- 2030-12-01
- First posted
- 2024-03-08
- Last updated
- 2025-12-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06300528. Inclusion in this directory is not an endorsement.